Video Assisted Thoracoscopic Surgery (VATS) - Surgical Pleurodesis vs Tube Drainage in Management of Malignant Pleural Effusion (MPE)
1 other identifier
interventional
60
1 country
1
Brief Summary
Malignant Pleural Effusion (MPE) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. It carries a burden on our patients with dyspnea being the most common symptom in most of cases. Management of symptomatic malignant pleural effusion remains to be a point of debate. Data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. Options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. Surgical intervention with abrasion pleurodesis or pleurectomy using VATS approach has been used in many studies. Using indwelling pleural catheters (IPCs) has also proved comparable efficacy at many clinical trials. In this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2023
CompletedFirst Submitted
Initial submission to the registry
May 13, 2023
CompletedFirst Posted
Study publicly available on registry
May 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2025
CompletedMay 24, 2023
May 1, 2023
2 years
May 13, 2023
May 22, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Total hospital stay
duration of hospital stay in days
3 months postoperative
duration of airleak
duration in days
3 months postoperative
Secondary Outcomes (3)
Status of performance
3 months
mortality
'3 months
Failure of management
3 months
Study Arms (2)
VATS surgical pleurodesis
OTHERPatients in whom we use VATS-surgical pleurodesis for malignant pleural effusion.
Tube drainage
OTHERPatients in whom we use tube drainage for malignant pleural effusion.
Interventions
Eligibility Criteria
You may qualify if:
- patients with symptomatic malignant pleural effusion. 2- symptomatic patients with shortness of breath. 3-Lung can be fully expanded.
You may not qualify if:
- Patients with non symptomatic malignant pleural effusion
- Pleural symphysis with no potentiality for re-expansion
- Patients managed surgically through open thoracotomy.
- Pleural effusion due to causes other than malignancy
- Loculated malignant effusion judged by chest ultrasound
- Trapped lung due to malignant pleural effusion assessed by multislice CT chest.,
- Refusal to share the research project and not to sign the consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut university heart hospital
Asyut, 2112, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle investigator
Study Record Dates
First Submitted
May 13, 2023
First Posted
May 24, 2023
Study Start
April 1, 2023
Primary Completion
March 31, 2025
Study Completion
April 30, 2025
Last Updated
May 24, 2023
Record last verified: 2023-05